SEP
RMD icon

Signature Equity Partners’s ResMed RMD Stock Holding History

Signature Equity Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.53K Hold
20
– – ﹤0.01% 985
2025
Q4 		$4.86K Buy
+20
New +$5.12K ﹤0.01% 989

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Signature Equity Partners's RMD Position: Q1 2026 in Review

Signature Equity Partners held its ResMed (RMD) position steady in Q1 2026 at 20 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #985.

Signature Equity Partners first reported a position in RMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.86K in Q4 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Signature Equity Partners held 20 shares of ResMed worth $4.53K as of Q1 2026.
  • Signature Equity Partners left its ResMed share count unchanged in Q1 2026.
  • ResMed made up ﹤0.01% of Signature Equity Partners's portfolio in Q1 2026, its #985 holding.
  • Signature Equity Partners first reported a position in ResMed in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's ResMed position peaked at $4.86K in Q4 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.